generics

Indian pharma post-COVID: On the innovation trail?

Post-COVID-19, India needs to strengthen its pharma R&D ecosystem to tap into emerging drug development opportunities and changing paradigms in the new drug development framework.....

Sanjay Singh Partner – Deal Advisory, Head of Lifesciences, KPMG in India
Patent expiries present a US$ 212 bn opportunity for Indian pharma

Sanjay Singh, Partner – Deal Advisory, Head of Lifesciences, KPMG in India, identifies new generics opportunities, established manufacturing ecosystem, growing penetration of health insurance and ta...


Subscribe To Newsletter

Get to know of latest happening in TPCI & in the world of trade and commerce